Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

A rare case has been reported of diffuse large B-cell lymphoma (DLBCL) presenting initially as cold agglutinin disease (CAD). The report, published in the Kaohsiung Journal of Medical Sciences, ...